/ONCO.ST
ONCO.ST Stock - Oncopeptides AB (publ)
Healthcare|BiotechnologySTO
$4.57+1.22%
+$0.06 (+1.22%) • Dec 23
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.60
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $5.03
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ONCO.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.52 – $4.62
TARGET (TP)$5.26
STOP LOSS$4.20
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-1.42
52W High$6.96
52W Low$1.10
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $31.65M | $35.22M | $8.36M | $118.30M | N/A |
| Gross Profit | $28.98M | $36.30M | $8.35M | $65.17M | $-14,403,000 |
| Gross Margin | 91.6% | 103.1% | 99.9% | 55.1% | N/A |
| Operating Income | $-283,498,000 | $-253,447,000 | $-349,350,000 | $-1,420,917,000 | $-1,591,279,000 |
| Net Income | $-284,607,000 | $-249,111,000 | $-337,951,000 | $-1,430,318,000 | $-1,594,693,000 |
| Net Margin | -899.3% | -707.3% | -4044.9% | -1209.1% | N/A |
| EPS | $-1.71 | $-1.96 | $-4.11 | $-19.00 | $-25.57 |
Company Overview
Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ONCO.STBeat Rate
45%
Last 11 quarters
Avg Surprise
-16.0%
EPS vs Estimate
Beats / Misses
5/6
Last 12 quarters
Latest EPS
$-0.27
Q4 2025
EPS Surprise History
Q1 24
-28.9%
$-0.90vs$-0.70
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Feb 19, 2026 | — | — | — | — |
Q4 2025 | Nov 5, 2025 | — | $-0.27 | — | — |
Q3 2025 | Aug 21, 2025 | — | $-0.30 | — | — |
Q2 2025 | May 15, 2025 | — | $-0.29 | — | — |
Q1 2025 | Feb 27, 2025 | — | $-0.39 | — | — |
Q4 2024 | Nov 7, 2024 | — | $-0.29 | — | — |
Q3 2024 | Aug 14, 2024 | — | $-0.48 | — | — |
Q2 2024 | May 30, 2024 | — | $-0.53 | — | — |
Q1 2024 | Feb 27, 2024 | $-0.70 | $-0.90 | -28.9% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-0.68 | $-0.45 | +34.5% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.68 | $-0.62 | +7.9% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-0.66 | $-0.79 | -18.6% | ✗ MISS |
Q1 2023 | Feb 16, 2023 | $-0.58 | $-1.01 | -74.6% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-0.72 | $-1.00 | -38.9% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.87 | $-0.79 | +9.2% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-2.15 | $-1.31 | +39.1% | ✓ BEAT |
Q1 2022 | Feb 17, 2022 | $-3.10 | $-5.23 | -68.7% | ✗ MISS |
Q4 2021 | Nov 24, 2021 | $-4.49 | $-10.33 | -130.1% | ✗ MISS |
Q3 2021 | Aug 19, 2021 | $-4.85 | $-0.32 | +93.4% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about ONCO.ST
What is ONCO.ST's current stock price?
Oncopeptides AB (publ) (ONCO.ST) is currently trading at $4.57 per share. The stock has moved +1.22% today.
What is the analyst price target for ONCO.ST?
No analyst price targets are currently available for this stock.
What sector is Oncopeptides AB (publ) in?
Oncopeptides AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is ONCO.ST's market cap?
Oncopeptides AB (publ) has a market capitalization of $0.98 billion, making it a small-cap company.
Does ONCO.ST pay dividends?
No, Oncopeptides AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBICO.ST
BICO Group AB (publ)
$19.00
Mkt Cap: $1.3B
CANTA.ST
Cantargia AB (publ)
$4.09
Mkt Cap: $1.0B
DMYD-B.ST
Diamyd Medical AB (publ)
$10.08
Mkt Cap: $1.4B
GENO.ST
Genovis AB (publ.)
$21.20
Mkt Cap: $1.4B
IBT-B.ST
Infant Bacterial Therapeutics AB (publ)
$49.00
Mkt Cap: $0.6B
ITECH.ST
I-Tech AB
$52.80
Mkt Cap: $0.6B
ORX.ST
Orexo AB (publ)
$27.30
Mkt Cap: $0.9B
SEZI.ST
Senzime AB (publ)
$5.26
Mkt Cap: $0.8B
SYNACT.ST
SynAct Pharma AB
$23.80
Mkt Cap: $1.3B
XSPRAY.ST
Xspray Pharma AB (publ)
$31.20
Mkt Cap: $1.1B
Explore stocks similar to ONCO.ST for comparison